Source: The Lancet
On Sept 1, 2008, Scotland launched routine vaccination for human papillomavirus (HPV) types 16 and 18, targeted at 12–13-year-old girls, of whom 92·4% were fully vaccinated in 2008–09.
This 7-year cross-sectional study explored the effectiveness of the bivalent vaccine in these vaccinated women who attended for routine cervical screening at age 20–21 years.
The results demonstrated that the bivalent vaccination has led to a startling reduction in vaccine and cross-protective HPV types 7 years after vaccination.
